NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Financial Statements
Industry: Surgical & Medical Instruments & Apparatus
In fiscal 2025, NEUROONE MEDICAL TECHNOLOGIES reported revenue of $9.1M, up 163.5% from $3.5M the year before. Net income was -$3.6M (a -39.6% net margin), or -$0.54 per diluted share. Gross margin was 56.5% and operating margin was -46.5%. Operating activities generated -$2.8M of cash, leaving -$2.9M of free cash flow. At fiscal year end, NEUROONE MEDICAL TECHNOLOGIES held $10.8M in total assets against $3.7M in total liabilities, including $6.6M of cash and equivalents.
Open the full interactive NEUROONE MEDICAL TECHNOLOGIES financials → Quarterly statements, key ratios, valuation history and price charts.
NEUROONE MEDICAL TECHNOLOGIES Key Stats
| Share Price | $1.10 |
|---|---|
| Market Cap | $9.6M |
| Revenue YoY Growth | +163.5% |
| 52-Week Range | $0.99 – $5.89 |
| Shares Outstanding | 8.7 million (basic, 2026 Q3) |
NEUROONE MEDICAL TECHNOLOGIES Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $178,146 | $171,169 | $2.0M | $3.5M | $9.1M |
| Gross Profit | — | -$97,749 | -$70,794 | $456,517 | $1.1M | $5.1M |
| Operating Income | -$4.9M | -$10.2M | -$10.0M | -$12.0M | -$11.9M | -$4.2M |
| Pre-Tax Income | -$13.6M | -$10.2M | -$10.0M | -$11.9M | -$12.3M | -$3.6M |
| Income Tax | — | -$271,122 | — | — | — | — |
| Net Income | -$13.6M | -$9.9M | -$10.0M | -$11.9M | -$12.3M | -$3.6M |
| Diluted EPS | -$15.12 | -$5.58 | -$3.78 | -$3.90 | -$2.76 | -$0.54 |
NEUROONE MEDICAL TECHNOLOGIES Quarterly Results
| 2025 Q4 | 2026 Q1 | 2026 Q2 | 2026 Q3 | |
|---|---|---|---|---|
| Revenue | $2.7M | $2.9M | $2.4M | $2.0M |
| Net Income | -$1.6M | -$1.4M | -$2.1M | -$2.0M |
| Diluted EPS | -$0.04 | -$0.18 | -$0.25 | -$0.28 |
NEUROONE MEDICAL TECHNOLOGIES Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.0M | $6.9M | $8.2M | $5.3M | $1.5M | $6.6M |
| Current Assets | $4.2M | $7.3M | $12.2M | $7.3M | $4.6M | $10.2M |
| Total Assets | $4.8M | $7.9M | $12.8M | $8.1M | $5.4M | $10.8M |
| Current Liabilities | $2.4M | $1.2M | $3.1M | $1.8M | $2.2M | $2.3M |
| Total Long-Term Debt | $254,328 | $202,895 | $119,556 | $55,284 | — | — |
| Total Liabilities | $2.7M | $1.4M | $3.2M | $1.8M | $4.5M | $3.7M |
| Shareholders' Equity | $2.1M | $6.6M | $9.6M | $6.2M | $822,013 | $7.1M |
NEUROONE MEDICAL TECHNOLOGIES Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$3.4M | -$8.6M | -$7.5M | -$12.9M | -$11.0M | -$2.8M |
| Cash From Investing | -$122,427 | -$67,079 | -$3.2M | $2.6M | -$120,197 | -$81,742 |
| Cash From Financing | $7.3M | $11.5M | $12.0M | $7.4M | $7.3M | $8.0M |
| Free Cash Flow | -$3.5M | -$8.7M | -$7.8M | -$13.3M | -$11.1M | -$2.9M |
Figures from NEUROONE MEDICAL TECHNOLOGIES's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full NEUROONE MEDICAL TECHNOLOGIES financials page for every line item.
NEUROONE MEDICAL TECHNOLOGIES Company Profile
| Ticker | NMTC |
|---|---|
| Exchange | Nasdaq |
| Industry | Surgical & Medical Instruments & Apparatus |
| Headquarters | Eden Prairie, Minnesota |
| Incorporated in | Delaware |
| Fiscal Year End | September 30 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001500198 |
Frequently Asked Questions
What was NEUROONE MEDICAL TECHNOLOGIES's revenue in fiscal 2025?
NEUROONE MEDICAL TECHNOLOGIES (NMTC) reported revenue of $9.1M for fiscal 2025.
What is NEUROONE MEDICAL TECHNOLOGIES's annual revenue history?
NEUROONE MEDICAL TECHNOLOGIES's annual revenue by fiscal year: 2020: $0; 2021: $178,146; 2022: $171,169; 2023: $2.0M; 2024: $3.5M; 2025: $9.1M.
What was NEUROONE MEDICAL TECHNOLOGIES's net income in fiscal 2025?
NEUROONE MEDICAL TECHNOLOGIES reported net income of -$3.6M for fiscal 2025.
What was NEUROONE MEDICAL TECHNOLOGIES's earnings per share (EPS) in fiscal 2025?
NEUROONE MEDICAL TECHNOLOGIES's diluted EPS was -$0.54 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did NEUROONE MEDICAL TECHNOLOGIES generate in fiscal 2025?
NEUROONE MEDICAL TECHNOLOGIES generated -$2.9M of free cash flow in fiscal 2025.
What was NEUROONE MEDICAL TECHNOLOGIES's revenue last quarter?
In its most recent reported quarter (2026 Q3), NEUROONE MEDICAL TECHNOLOGIES reported revenue of $2.0M.
How many shares of NEUROONE MEDICAL TECHNOLOGIES are outstanding?
NEUROONE MEDICAL TECHNOLOGIES reported a weighted average of 8.7 million basic shares outstanding in 2026 Q3.
What is NEUROONE MEDICAL TECHNOLOGIES's market cap?
Based on its latest closing price, NEUROONE MEDICAL TECHNOLOGIES (NMTC) has a market capitalization of about $9.6M.
When does NEUROONE MEDICAL TECHNOLOGIES's fiscal year end?
NEUROONE MEDICAL TECHNOLOGIES's fiscal year end, as registered with the SEC, is September 30.
Where is NEUROONE MEDICAL TECHNOLOGIES headquartered?
NEUROONE MEDICAL TECHNOLOGIES lists its business address in Eden Prairie, Minnesota in its SEC filings.
NEUROONE MEDICAL TECHNOLOGIES Competitors & Similar Companies
See all 109 Surgical & Medical Instruments & Apparatus companies →